ENGN ENGENE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended July 31, 2026, ENGENE THERAPEUTICS INC reported revenue of n/a, net income of −$32.5M and diluted EPS of −$0.47; for the fiscal year ended October 2025 revenue was n/a.
ENGN annual revenue and earnings
- Fiscal year ended Oct 2025: revenue n/a, gross profit n/a, operating income −$123M, net income −$117M (margin n/a), EPS $2.29
- Fiscal year ended Oct 2024: revenue n/a, gross profit n/a, operating income −$62.3M, net income −$55.1M (margin n/a), EPS $1.46
- Fiscal year ended Oct 2023: revenue n/a, gross profit n/a, operating income −$26.1M, net income −$99.9M (margin n/a), EPS $151.22
- Fiscal year ended Oct 2022: revenue n/a, gross profit n/a, operating income −$19.4M, net income −$24.5M (margin n/a), EPS $44.30
ENGN quarterly revenue and earnings
- Quarter ended Jul 31, 2026: revenue n/a, net income −$32.5M, EPS −$0.47
- Quarter ended Apr 30, 2026: revenue n/a, net income −$30.2M, EPS −$0.43
- Quarter ended Jan 31, 2026: revenue n/a, net income −$29.8M, EPS $0.44
- Quarter ended Oct 31, 2025 (from the annual report): revenue n/a, net income −$37.9M, EPS $2.89
- Quarter ended Jul 31, 2025: revenue n/a, net income −$29.0M, EPS −$0.57
- Quarter ended Apr 30, 2025: revenue n/a, net income −$25.8M, EPS −$0.51
- Quarter ended Jan 31, 2025: revenue n/a, net income −$24.6M, EPS $0.48
- Quarter ended Oct 31, 2024 (from the annual report): revenue n/a, net income −$15.3M, EPS $0.30
- Quarter ended Jul 31, 2024: revenue n/a, net income −$14.1M, EPS $0.32
- Quarter ended Apr 30, 2024: revenue n/a, net income −$15.0M, EPS $0.38
- Quarter ended Jan 31, 2024: revenue n/a, net income −$10.7M, EPS $0.46
- Quarter ended Oct 31, 2023 (from the annual report): revenue n/a, net income −$82.5M, EPS $120.08
- Quarter ended Jul 31, 2023: revenue n/a, net income −$4.72M, EPS $8.55
- Quarter ended Apr 30, 2023: revenue n/a, net income −$5.28M, EPS $9.30
- Quarter ended Jan 31, 2023: revenue n/a, net income −$7.42M, EPS $13.29
ENGN cash flow, buybacks and dividends
- Fiscal year ended Oct 2025: operating cash flow −$99.2M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Oct 2024: operating cash flow −$48.3M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Oct 2023: operating cash flow −$24.7M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Oct 2022: operating cash flow −$17.6M, share buybacks n/a
ENGN balance sheet
- Jul 31, 2026: cash $41.0M, total assets $288M, total liabilities $58.0M, shareholders' equity $230M
- Apr 30, 2026: cash $29.8M, total assets $308M, total liabilities $52.4M, shareholders' equity $255M
- Jan 31, 2026: cash $36.6M, total assets $337M, total liabilities $55.6M, shareholders' equity $282M
- Oct 31, 2025: cash $50.2M, total assets $221M, total liabilities $53.8M, shareholders' equity $168M
- Jul 31, 2025: cash $32.6M, total assets $246M, total liabilities $44.9M, shareholders' equity $201M
- Apr 30, 2025: cash $57.5M, total assets $267M, total liabilities $39.4M, shareholders' equity $227M
- Jan 31, 2025: cash $62.3M, total assets $286M, total liabilities $36.0M, shareholders' equity $250M
- Oct 31, 2024: cash $173M, total assets $311M, total liabilities $38.6M, shareholders' equity $273M
Is ENGN profitable?
No. ENGENE THERAPEUTICS INC lost $130M over the last four quarters.
What is ENGN's EPS?
Diluted earnings per share over the last four quarters were $2.43; −$0.47 in the latest quarter.